It's about giving more options to patients Interestingly, Dr. Agarwal, that is now associated with UChicago, our 7th CSS, and who cited this when he on-boarded our Ph. 2:
“This technology harnesses the power of near infrared light produced by a laser to destroy localized bladder cancer cells that have not responded to standard of care therapy such as BCG. It gives patients an option to consider before bladder removal,” stated Dr. Piyush Agarwal, Professor of Surgery and Urology, Director of the Bladder Cancer Program and Fellowship Director of Urologic Oncology at the University of Chicago Medicine, in a release. was at this position before:
Piyush Agarwal, M.D., head of the Bladder Cancer Section in the National Cancer Institute (NCI) Center for Cancer Research's (CCR) Urologic Oncology Branch and, for those curious to know more about what TLT would go through, sat on the FDA Oncologic Drugs Advisory Committee (ODAC) that gave its position on Keytruda in 2021:
https://www.fda.gov/media/147857/download (see in gray, the FDA position to Merck arguments)